Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cance...(prove overallsurvival for metastatic bre...),Health

Date:6/1/2008

prove overall survival for metastatic breast cancer," Dr. Lum said. "Although high numbers of remissions were not induced, we may have improved the patients' longevity and quality of life without undue toxicities. The predominant side effects were chills, fever, headaches, and transient hypotension that were controlled with medications and fluid support."

"It appears that infusions of targeted T cells have boosted the immune system to create a more efficient tumor killing machine within the patient's body," he said. "Although the median survival rate for all patients remains undefined, survival rates for the HER2 (0-2+) cohort is 21.3 months." He said that the immunotherapy may be vaccinating the patient's immune system to their own tumors. This is encouraging given that the tumor burden was high in the majority of women who had failed other therapies and the prognosis is poor.

In addition to Dr. Lum, abstract authors include: Zaid Al-Kadhimi, M.D., Associate Director of Immunotherapy, Karmanos Cancer Institute; Cassara Skuba, B.S., Supervisor of Cell Processing Facility, Karmanos Cancer Institute; Rebecca Sandborg, Ph.D., Karmanos Cancer Institute; Ritesh Rathore, M.D., Chief of Hematology/Oncology, Assistant Professor of Medicine, Boston University, Roger Williams Hospital, Providence, RI; Qin Liu, Ph.D., Assistant Professor of Medicine, University of Massachusetts, Worcester, MA; and Co-Leaders of the Karmanos Cancer Center BMT Multidisciplinary team Voravit Ratanatharathorn, M.D. and Joseph Uberti, M.D., Ph.D.

The Phase I Clinical Trial was supported by a National Cancer Institute ROI CA92344 grant, a translational grant from the Leukemia & Lymphoma Society Michigan Life Science Grant, funds from Roger Williams Hospital, Providence RI and funds from the Karmanos Cancer Institute.

The Barbara Ann Karmanos Cancer Institute

The Barbara Ann Karmanos Cancer Institute in Detroit is one of 41 National Cancer Institute (NCI)-designated
'/>"/>

SOURCE The Barbara Ann Karmanos Cancer Institute Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
2. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
3. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Novel Technology Breaks Through Cancer Pain
11. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug